These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35767280)

  • 21. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.
    Georgoulias G; Zaravinos A
    Front Immunol; 2022; 13():1006665. PubMed ID: 36389735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
    Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
    Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
    Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
    Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
    Zhang J; An L; Zhou X; Shi R; Wang H
    Ann Transl Med; 2021 Apr; 9(7):551. PubMed ID: 33987249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
    Zhang C; Shen L; Qi F; Wang J; Luo J
    J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-related prognostic genes signatures in the tumor microenvironment of sarcoma.
    Wang J; Gong M; Xiong Z; Zhao Y; Xing D
    Math Biosci Eng; 2021 Mar; 18(3):2243-2257. PubMed ID: 33892543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling most abundant mutational signatures in head and neck cancer.
    Plath M; Gass J; Hlevnjak M; Li Q; Feng B; Hostench XP; Bieg M; Schroeder L; Holzinger D; Zapatka M; Freier K; Weichert W; Hess J; Zaoui K
    Int J Cancer; 2021 Jan; 148(1):115-127. PubMed ID: 32930393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor immunogenomic signatures improve a prognostic model of melanoma survival.
    Morales L; Simpson D; Ferguson R; Cadley J; Esteva E; Monson K; Chat V; Martinez C; Weber J; Osman I; Kirchhoff T
    J Transl Med; 2021 Feb; 19(1):78. PubMed ID: 33596955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.
    Wang C; Liang H; Lin C; Li F; Xie G; Qiao S; Shi X; Deng J; Zhao X; Wu K; Zhang X
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
    Shen R; Liu B; Li X; Yu T; Xu K; Ma J
    BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
    An Y; Yang Q
    Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a pyroptosis-related prognostic signature in breast cancer.
    Chen H; Luo H; Wang J; Li J; Jiang Y
    BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prognostic Molecular Signature of N⁶-Methyladenosine Methylation Regulators for Soft-Tissue Sarcoma from The Cancer Genome Atlas Database.
    Hou M; Guo X; Chen Y; Cong L; Pan C
    Med Sci Monit; 2020 Dec; 26():e928400. PubMed ID: 33370249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.